Sphingosine 1 phosphate receptor agonists for neuroprotection
Methods of treating conditions for which S1P-mediated neuroprotection is medically indicated, comprising administering to a subject in need thereof an agonist of the sphingosine 1-phosphate receptor (S1P receptor); such as a compound having the following structure (See Formula 1): or a pharmaceutically acceptable salt, stereoisomer, homolog, hydrate or solvate thereof.
1. A method of treating a patient with a disease selected from the group consisting of Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, and Rett syndrome, the method comprising administering to the patient a therapeutically effective amount of a compound having one of the following structures:
or a pharmaceutically acceptable salt, stereoisomer, homolog, hydrate or solvate thereof.
2. The method of claim 1 , wherein treating the patient with the therapeutically effective amount of the compound is evidenced by a reduction in spinal cord inflammation in the patient.
3. The method of claim 1 , wherein treating the patient with the therapeutically effective amount of the compound is evidenced by a reduction in spinal cord axial demyelination.
4. The method of claim 1 , wherein treating the patient with the therapeutically effective amount of the compound is evidenced by a reduction in T cell expansion, a decrease in monocyte infiltration into the spinal cord, limiting microglia expansion into the spinal cord, or any combination thereof.
5. The method of claim 1 , wherein treating the patient with the therapeutically effective amount of the compound is evidenced by a reduction in brain volume loss.
6. The method of claim 1 , wherein treating the patient with the therapeutically effective amount of the compound is evidenced by a reduction in MAO-B activity.
7. The method of claim 1 , wherein the compound has the following structure:
or a pharmaceutically acceptable salt, stereoisomer, homolog, hydrate or solvate thereof.
8. The method of claim 7 , wherein the compound is ozanimod.
9. The method of claim 1 , wherein the compound has the following structure:
or a pharmaceutically acceptable salt, homolog, hydrate or solvate thereof.
10. The method of claim 1 , wherein the compound has the following structure:
or a pharmaceutically acceptable salt, stereoisomer, homolog, hydrate or solvate thereof.
11. The method of claim 1 , wherein the compound has the following structure:
or a pharmaceutically acceptable salt, stereoisomer, homolog, hydrate or solvate thereof.
12. The method of claim 1 , wherein the compound has the following structure:
or a pharmaceutically acceptable salt, stereoisomer, homolog, hydrate or solvate thereof.